IPO of Control Bionics Limited
Control Bionics (ASX: CBL) designs, manufactures and sells communication technologies used by individuals suffering from diseases that impede their ability to communicate, such as motor neurone disease, multiple sclerosis, as well as spinal injuries. The flagship product, the NeuroNode Trilogy, allows users to operate and communicate via a computer using intentional thought and the body’s own neuroelectric signals.
Control Bionics is headquartered in Melbourne, Australia, with an existing operating office in the United States, currently selling its products in the United States, Australia and Canada.
Control Bionics completed its listing of shares on the Australian Securities Exchange raising A$15 million in December 2020. The funds will be used to increase the sales and marketing capabilities of the business as well as to support future research and development.
BDO was engaged by Control Bionics to perform the Independent Accountant, Independent Tax Adviser and Auditor roles for their IPO on the ASX.